Source: resolution_news
Source ID: resolution_news:2af35fd1fe9d8ee2c48983141182df70:ARCT
URL: https://news.google.com/rss/articles/CBMimwJBVV95cUxORzRuTDlyOXAwSGQ5dWJzNlVDakg1RHVVNFBVTEhnUzBhZWlSMkhoTktQcUhISDJBdUg3Sk9nMmF3b0pIRHMxNFIwXzRMcnRWelBwMVdJdGdacVpHZFhvb0d4bUMyYjljUlVMUmhrQ1BDZTlZWUlFNjBVTmpWa2ttenF3UXItSDJGVko1OFUzMzQ1M1E3bm5CbmttbFg5dDZ3bFI1SEE0M0JmaUFZc3VrMmhTSmtCZWd6MU85SUdGdTROem9Xc3BCN1VpVkhCNi04S0U2Z2YxUFRCcm9iUDFTZUlqSjNiY2VKbklXYWxIYlc2ZmhKWVdGOGYwcjd0X093RkpJUVlSSUZRNFdzSEZhWmdXQWJRX3I1YUdR?oc=5
Symbol: (ARCT)
Published: 2026-09-23 03:00:00 EDT
Time precision: minute
Title: Arcturus Therapeutics Announces Interim OTC Deficiency Phase 2 Results and Introduces LUNAR 2.0™ Next-Generation mRNA Delivery Platform - Business Wire

Arcturus Therapeutics Announces Interim OTC Deficiency Phase 2 Results and Introduces LUNAR 2.0™ Next-Generation mRNA Delivery Platform
Business Wire